Alternative Ii-independent antigen-processing pathway in leukemic blasts involves TAP-dependent peptide loading of HLA class II complexes.
During HLA class II synthesis in antigen-presenting cells, the invariant chain (Ii) not only stabilizes HLA class II complexes in the endoplasmic reticulum, but also mediates their transport to specialized lysosomal antigen-loading compartments termed MIICs. This study explores an alternative HLA class II presentation pathway in leukemic blasts that involves proteasome and transporter associated with antigen processing (TAP)-dependent peptide loading. Although HLA-DR did associate with Ii, Ii silencing in the human class II-associated invariant chain peptide (CLIP)-negative KG-1 myeloid leukemic cell line did not affect total and plasma membrane expression levels of HLA-DR, as determined by western blotting and flow cytometry. Since HLA-DR expression does require peptide binding, we examined the role of endogenous antigen-processing machinery in HLA-DR presentation by CLIP(-) leukemic blasts. The suppression of proteasome and TAP function using various inhibitors resulted in decreased HLA-DR levels in both CLIP(-) KG-1 and ME-1 blasts. Simultaneous inhibition of TAP and Ii completely down-modulated the expression of HLA-DR, demonstrating that together these molecules form the key mediators of HLA class II antigen presentation in leukemic blasts. By the use of a proteasome- and TAP-dependent pathway for HLA class II antigen presentation, CLIP(-) leukemic blasts might be able to present a broad range of endogenous leukemia-associated peptides via HLA class II to activate leukemia-specific CD4(+) T cells.
van Luijn
Marvin M
MM
Department of Hematology, Cancer Center Amsterdam, VU Institute for Cancer and Immunology, VU University Medical Center, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands. m.luijn@vumc.nl
Chamuleau
Martine E D
ME
Ressing
Maaike E
ME
Wiertz
Emmanuel J
EJ
Ostrand-Rosenberg
Suzanne
S
Souwer
Yuri
Y
Zevenbergen
Adri
A
Ossenkoppele
Gert J
GJ
van de Loosdrecht
Arjan A
AA
van Ham
S Marieke
SM
D018528:ATP-Binding Cassette Transporters / Q000502:physiology*; D017951:Antigen Presentation; D000944:Antigens, Differentiation, B-Lymphocyte / Q000502:physiology*; D001752:Blast Crisis / Q000276:immunology*; D045744:Cell Line, Tumor; D006684:HLA-DR Antigens / Q000502:physiology*; D000949:Histocompatibility Antigens Class II / Q000502:physiology*; D006801:Humans; D007951:Leukemia, Myeloid / Q000276:immunology / Q000473:pathology*; D046988:Proteasome Endopeptidase Complex / Q000502:physiology
D018528:ATP-Binding Cassette Transporters; D000944:Antigens, Differentiation, B-Lymphocyte; D006684:HLA-DR Antigens; D000949:Histocompatibility Antigens Class II; C045084:invariant chain; C477327:transporter associated with antigen processing (TAP); D046988:Proteasome Endopeptidase Complex
Traffic. 2000 Feb;1(2):152-60
11208095
Blood. 2003 Dec 1;102(12):4137-42
12920018
J Immunol. 2005 Feb 15;174(4):1811-9
15699107
Cancer Immunol Immunother. 2005 Aug;54(8):721-8
16010587
Nature. 1990 Dec 13;348(6302):600-5
2250716
J Exp Med. 1992 Sep 1;176(3):657-66
1512535
Nature. 1990 Jun 14;345(6276):615-8
2190094
Proc Natl Acad Sci U S A. 1997 Jun 24;94(13):6886-91
9192661
Cell. 1990 Apr 6;61(1):171-83
2156628
Immunology. 1983 Dec;50(4):613-24
6197354
Science. 2005 Jan 28;307(5709):593-6
15591165
Proc Natl Acad Sci U S A. 1996 Jan 9;93(1):241-4
8552613
Blood. 1996 Jun 15;87(12):5104-12
8652823
Nat Immunol. 2008 May;9(5):558-66
18376402
J Exp Med. 2007 Aug 6;204(8):1863-73
17620360
J Exp Med. 2000 May 1;191(9):1513-24
10790426
J Immunol. 1994 Aug 15;153(4):1487-94
8046228
J Mol Biol. 2007 May 25;369(1):95-107
17418234
Nature. 1991 Dec 5;354(6352):392-4
1956401
Haematologica. 2010 Mar;95(3):485-93
19903675
Proc Natl Acad Sci U S A. 2005 Apr 5;102(14):5144-9
15793001
Immunobiology. 2008;213(1):75-86
18207029
J Immunol. 2008 Oct 1;181(7):4894-907
18802093
Nature. 1995 Jun 29;375(6534):802-6
7596415
Leukemia. 2000 May;14(5):859-62
10803518
Cancer Immunol Immunother. 2008 Mar;57(3):389-98
17724589
J Immunol. 2001 Sep 1;167(5):2632-41
11509605
Nature. 2003 Sep 25;425(6956):397-402
14508489
Nat Methods. 2005 May;2(5):357-62
15846363
Cancer Res. 2006 Jan 15;66(2):1147-54
16424052
J Biosci. 2006 Mar;31(1):137-55
16595883
Nature. 2002 Oct 3;419(6906):480-3
12368856
Arch Dermatol Res. 2001 Mar;293(3):147-58
11357229
J Cell Sci. 2004 Aug 15;117(Pt 18):4219-30
15316082
J Cell Sci. 1997 Mar;110 ( Pt 5):597-609
9092942
Proc Natl Acad Sci U S A. 1993 Oct 1;90(19):9130-4
8415666
Immunotherapy. 2010 Jan;2(1):85-97
20635891
Proc Natl Acad Sci U S A. 1992 Mar 15;89(6):2282-6
1549594
J Exp Med. 1994 Sep 1;180(3):1107-13
8064228
Immunity. 2005 May;22(5):571-81
15894275
Proc Natl Acad Sci U S A. 2005 May 31;102(22):7922-7
15894616
J Cell Sci. 1993 Nov;106 ( Pt 3):831-46
8308066
Cell. 1993 Feb 26;72(4):635-48
7679955
Nat Immunol. 2005 Mar;6(3):287-94
15711549